Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ECG vs RAL: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ECG Wins Head-to-Head Institutional Verdict (3–3 across 6 Pillars · 6–4 Matrix Metrics)

ECG Overall Winner 6-Pillar Tally: ECG 3 – 3 RAL Matrix Metrics: ECG 6 – 4 RAL

As of Nov 17, 2026, Everus Construction Group, Inc. (ECG) is the stronger overall head-to-head candidate over Ralliant Corporation (RAL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ECG carries a Unified Composite Score of 50.8/100 (HOLD) at $84.73 (11.7x Forward P/E, 8.2% operating margin), whereas RAL carries 35.6/100 (SELL) at $67.14 (18.6x Forward P/E, 15.0% operating margin).

  • Technical & Structure Timing Caution: ECG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.1); meanwhile RAL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ECG vs RAL
ECG NYSE Head-to-Head Winner
Everus Construction Group, Inc.
Operative Builders
$84.73
+2.18% 1D
Market Cap $4.4B
TTM Revenue $4.66B
Forward P/E 11.7x
Beta / 30D Vol 2.16β · 127% Vol
Unified Composite Score
50.8 / 100 HOLD
Tech 60.0 Fund 58.0 Flow 54.0 Mom 58.9
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.6%), weak momentum, RSI 40
RSI-14: 40.1 · SMA20: $92.92 · SMA50: $107.29
RAL NYSE
Ralliant Corporation
Industrial Instruments For Measurement, Display, And Control
$67.14
-0.79% 1D
Market Cap $7.6B
TTM Revenue $2.28B
Forward P/E 18.6x
Beta / 30D Vol 1.60β · 67% Vol
Unified Composite Score
35.6 / 100 SELL
Tech 20.0 Fund 43.0 Flow 50.0 Mom 68.2
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 46
RSI-14: 46.3 · SMA20: $68.59 · SMA50: $69.11

6-Pillar Scorecard Institutional Category Breakdown (ECG 3 – 3 RAL)

Columns: Metric · ECG · RAL
1. Valuation Multiples ECG
Forward P/E 11.7x 18.6x
Trailing P/E 15.1x 21.3x
PEG Ratio N/M N/M
EV / Revenue 1.0x 3.3x
2. Growth & Scale ECG
Revenue Growth (YoY) +40.3% +17.2%
Earnings Growth (YoY) +61.3% +120.0%
TTM Revenue (USD) $4.66B $2.28B
Market Cap $4.4B $7.6B
3. Profitability & Quality RAL
Gross Margin 13.6% 51.6%
Operating Margin 8.2% 15.0%
Net Profit Margin 6.2% -52.1%
Return on Equity (ROE) 40.3% -51.8%
4. Balance Sheet & Cash Flow RAL
Cash Generation (TTM) $237M $460M EBITDA
Cash Flow Margin 5.1% 20.2% EBITDA Mgn
Net Cash / Leverage $439M Net Debt (0.81x D/E) $14.59 Book/Sh · -51.8% ROE
Dividend Yield None (0.00%) 0.28%
5. Options & Positioning ECG
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 93.7% (12th %ile) 41.7% (58th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat RAL
OpEx & R&D Intensity 5.4% of Rev ($252M) 36.6% of Rev ($833M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Scale & Operating Efficiency Moat
Supply-Chain Role Engineering & Construction Operator Electronic Components Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ECG (6) vs RAL (4)
Institutional Metric ECG RAL Criterion Row Edge
Market Capitalization
Scale
$4.4B $7.6B Larger Scale RAL
Trailing P/E Ratio
Valuation
15.1x 21.3x Lower Multiple ECG
Forward P/E Ratio
Valuation
11.7x 18.6x Lower Multiple ECG
Revenue Growth (YoY)
Growth
+40.3% +17.2% Higher Growth ECG
Operating Margin (TTM)
Profitability
8.2% 15.0% Higher Margin RAL
Net Profit Margin
Profitability
6.2% -52.1% Higher Margin ECG
Return on Equity (ROE)
Capital Efficiency
40.3% -51.8% Higher ROE ECG
52-Week Range Position
Momentum
14% ($70–$172) 78% ($37–$75) Stronger Trend RAL
Beta / 30D Volatility
Risk Regime
2.16β · 127% Vol 1.60β · 67% Vol Lower Realized Risk RAL
Unified Institutional Score
Composite Signal
50.8 / 100 (HOLD) 35.6 / 100 (SELL) Higher Composite ECG
Trailing 12M Revenue (USD)
Operating Scale
$4.66B $2.28B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
13.6% 51.6% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 1.0x EV/Rev N/M PEG · 3.3x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$237M ($439M Net Debt (0.81x D/E)) $460M EBITDA ($14.59 Book/Sh · -51.8% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RAL +21.85 pp
ECG: -22.05% · RAL: -0.2%
3M Horizon RAL +35.55 pp
ECG: -34.6% · RAL: +0.95%
6M Horizon RAL +56.65 pp
ECG: -42.07% · RAL: +14.58%
1Y Horizon RAL +47.52 pp
ECG: -6.04% · RAL: +41.48%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ECG vs RAL. Trailing 12-month operating profitability (ECG 8.2% vs RAL 15.0%) and valuation multiples (ECG 11.7x vs RAL 18.6x Forward P/E) are benchmarked directly in Pillar 4 below.

ECG ADR TTM Benchmark FX-Normalized USD
TTM Revenue$4.66B
Gross Margin13.6%
Op. Margin8.2%
ROE / Fwd P/E40.3% · 11.7x
RAL ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.28B
Gross Margin51.6%
Op. Margin15.0%
ROE / Fwd P/E-51.8% · 18.6x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ECG BREAKDOWN
135d in phase · OBV ACCUMULATION
Current IV 93.7%
IV Percentile 12th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow ACCUMULATION
Exact ECG Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RAL UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 41.7%
IV Percentile 58th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RAL Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ECG Moat Profile High-Margin Pricing Power Moat
Engineering & Construction Operator
Competes within the Engineering & Construction value chain with $4.4B market capitalization and 8.2% operating margin.
OpEx & R&D Reinvestment 5.4% of Rev ($252M)
90D Engineering Disclosures 0 Published
RAL Moat Profile Scale & Operating Efficiency Moat
Electronic Components Operator
Competes within the Electronic Components value chain with $7.6B market capitalization and 15.0% operating margin.
OpEx & R&D Reinvestment 36.6% of Rev ($833M)
90D Engineering Disclosures 0 Published

Investor FAQ ECG vs RAL Key Questions & Quantitative Answers

As of Nov 17, 2026, Everus Construction Group, Inc. (ECG) is the stronger overall head-to-head candidate over Ralliant Corporation (RAL) in the Tradestie Institutional Equity Comparison Engine, winning 6–4 core matrix metrics and 3–3 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Options & Positioning). ECG carries a Unified Composite Score of 50.8/100 (HOLD) at $84.73 (11.7x Forward P/E, 8.2% operating margin), whereas RAL carries 35.6/100 (SELL) at $67.14 (18.6x Forward P/E, 15.0% operating margin). Technical & Structure Timing Caution: ECG is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 40.1); meanwhile RAL trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 46.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

ECG leads the Growth & Scale pillar: ECG posts +40.3% YoY revenue growth and +61.3% YoY earnings growth on $4.66B TTM revenue (13.6% gross margin, 8.2% operating margin), compared with RAL at +17.2% YoY revenue growth and +120.0% YoY earnings growth on $2.28B TTM revenue (51.6% gross margin, 15.0% operating margin). On trailing 12-month operating scale, ECG generates $4.66B in USD-normalized revenue versus $2.28B for RAL. In operating R&D and SG&A reinvestment, ECG deploys 5.4% of Rev ($252M) (0 90-day corporate R&D disclosures) versus 36.6% of Rev ($833M) (0 disclosures) for RAL.

ECG screens cheaper on headline valuation multiples. ECG trades at 11.7x Forward P/E, 15.1x Trailing P/E, N/M PEG, and 1.0x EV/Revenue (5.1% FCF margin), whereas RAL trades at 18.6x Forward P/E, 21.3x Trailing P/E, N/M PEG, and 3.3x EV/Revenue (20.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ECG (40.3% ROE) versus RAL (-51.8% ROE) capital efficiency.

In options market volatility and institutional positioning, ECG carries 93.7% implied volatility (12th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (2.16β · 127% Vol realized risk). By comparison, RAL carries 41.7% implied volatility (58th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.60β · 67% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.